4-4-difluoro-4-bora-3a-4a-diaza-s-indacene and Skin-Neoplasms

Melanoma is the most threatening form of metastatic skin cancer that develops from melanocytes and causes a large majority of deaths due to poor therapeutic prognosis. It has significant limitations in treatment because it shows great resistance to chemotherapy, radiotherapy, and other therapeutic methods. A noninvasive and clinically accepted therapeutic modality, photodynamic therapy (PDT), is a promising treatment option, but it is limitedly applied for melanoma skin cancer treatment. This is because most of the photosensitizers are unlikely to be expected to have a remarkable effect on melanoma due to drug efflux by melanin pigmentation and intrinsic antioxidant defense mechanisms. Moreover, melanin is a dominant absorber in the spectral region of 500-600 nm that can cause the decreased photoreaction efficiency of photosensitizers. Herein, to overcome these drawbacks, we have developed a phenylthiourea-conjugated BODIPY photosensitizer (

Topics: Antineoplastic Agents; Biocompatible Materials; Boron Compounds; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Humans; Materials Testing; Melanoma; Melanoma, Cutaneous Malignant; Molecular Structure; Monophenol Monooxygenase; Particle Size; Phenylthiourea; Photochemotherapy; Photosensitizing Agents; Skin Neoplasms